Cytomegalovirus test – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:02:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cytomegalovirus test – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Preventing Cytomegalovirus Infection Using Valganciclovir in Kidney Transplant Patients https://clinicaltrials.eu/trial/study-on-preventing-cytomegalovirus-infection-using-valganciclovir-in-kidney-transplant-patients/ Wed, 29 Apr 2026 15:00:40 +0000 https://clinicaltrials.eu/trial/study-on-preventing-cytomegalovirus-infection-using-valganciclovir-in-kidney-transplant-patients/ This clinical trial is focused on studying the effectiveness of a new preventive strategy for managing cytomegalovirus (CMV) infection in patients who have received a kidney transplant. CMV is a common virus that can cause serious health issues in people with weakened immune systems, such as those who have undergone organ transplants. The study will compare two different approaches to preventing CMV infection: a new strategy that is guided by the patient’s immune response and the standard universal preventive approach.

The treatment being tested in this study is called Valganciclovir, which is a medication used to prevent CMV infections. Participants in the study will receive this medication in the form of a film-coated tablet. The study will last for a period of six months following the kidney transplant, during which the effectiveness of the new preventive strategy will be evaluated. Some participants will receive the new strategy, while others will follow the standard preventive approach, and some may receive a placebo.

The main goal of the study is to determine how well the new strategy works in preventing CMV infections compared to the standard approach. Researchers will monitor the participants for any signs of CMV infection and will also assess the need for additional antiviral treatments. The study aims to provide valuable insights into improving the care and outcomes for kidney transplant patients at risk of CMV infection.

]]>